Colistin-associated Stevens-Johnson syndrome and toxic epidermal necrolysis reactions: a retrospective case-non-case pharmacovigilance study

References

• Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, et al. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147–176.
   PubMed Web of Science ®Google Scholar
• Czarnobilska E, Obtułowicz K, Wsołek K. Reakcja alergiczna typu IV i jej podtypy [Type IV of hypersensitivity and its subtypes]. Przegl Lek. 2007;64(7–8):506–508.
   PubMedGoogle Scholar
• Oakley AM, and Krishnamurthy K. Stevens Johnson Syndrome. [Updated April 19 2021.] In: StatPearls[ Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Jan. Internet. https://www.ncbi.nlm.nih.gov/books/NBK459323/.
   Google Scholar
• Borrelli EP, Lee EY, Descoteaux AM, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US food and drug administration adverse event reporting system. Epilepsia. 2018;59(12):2318–2324.
   PubMed Web of Science ®Google Scholar
• Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective regiscar study. Br J Dermatol. 2013;169(5):1071–1080.
   PubMed Web of Science ®Google Scholar
• Kim HI, Kim SW, Park GY, et al. Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients. Korean J Intern Med. 2012;27(2):203–210.
   PubMed Web of Science ®Google Scholar
• Hsu DY, Brieva J, Silverberg NB, et al. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016Jul;136(7):1387–1397. Epub 2016 Mar 30. PubMed PMID: 27039263.
   PubMed Web of Science ®Google Scholar
• Stevens-Johnson syndrome/toxic epidermal necrolysis - genetics home reference - NIH. (2020, May 12). cited 2020 May 18 from https://ghr.nlm.nih.gov/condition/stevens-johnson-syndrome-toxic-epidermal-necrolysis#definition
   Google Scholar
• Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol. 2017;177(4):924–935.
   PubMed Web of Science ®Google Scholar
• Yang CW, Cho YT, Chen KL, et al. Long-term sequelae of Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2016;96(4):525–529.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clinl Infect Dis. 2005 May 1;40(9):1333–1341.
   PubMed Web of Science ®Google Scholar
• Colistimethate. In: Lexi-drugs online [database on the Internet]. Hudson (OH): Lexicomp, Inc.; 2016 [ updated 18 May 2020; cited 19 May 2020]. Available from: http://online.lexi.com. Subscription required to view.
   Google Scholar
• Patek TM, Teng C, Kennedy KE, et al. Comparing acute kidney injury reports among antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Drug Saf. 2019;43(1):17–22.
   Web of Science ®Google Scholar
• Spapen H, Jacobs R, Van Gorp V, et al. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1(1):14.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. (2018, June 04). Questions and answers on FDA’s Adverse Event Reporting System (FAERS). Retrieved 2020 Jun 11, from https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers
   Google Scholar
• Chedid V, Vijayvargiya P, Camilleri M. Advantages and limitations of the federal adverse events reporting system in assessing adverse event reporting for eluxadoline. Clin Gastroenterol Hepatol. 2018;16(3):336–338.
   PubMed Web of Science ®Google Scholar
• Colistin. (2020, March 15). cited 2020 Mar 16, from https://www.drugbank.ca/drugs/DB00803
   Google Scholar
• Dean AG, Sullivan KM, Soe MM OpenEpi: open source epidemiologic statistics for public health, version. www.OpenEpi.com, updated 2013/april/06, cited 2020 march 19.
   Google Scholar
• National library of medicine (U.S.). DailyMed. Bethesda, MD: U.S. National Library of Medicine, National Institutes of Health, Health & Human Services; 2005.
   Google Scholar
• Colistin. package insert. Toronto, ON Canada: Fresenius Kabi Canada Ltd.; 2017.
   Google Scholar
• Coly-Mycin M Parenteral. Rochester, MI: Parkedale Pharmaceuticals Inc.; 2006. package insert.
   Google Scholar
• IBM micromedex® DRUGDEX® (electronic version). IBM Watson health, Greenwood Village, Colorado USA. Available at: https://www.micromedexsolutions.com/ (cited 2020 may 28).
   Google Scholar
• Ciprofloxacin. Whippany, NJ: Bayer Healthcare Pharmaceuticals Inc; 2016. Package insert.
   Google Scholar
• Amphotericin B. Big Flats, NY: X-Gen Pharmaceuticals Inc; 2009. Package insert.
   Google Scholar
• Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157–2164.
   PubMed Web of Science ®Google Scholar
• Weber J. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, and Velo GD, editors. Side-effects of anti-inflammatory drugs, advances in inflammation research. 1984;1–7. New York: Raven Press.
   Google Scholar
• Hoffman KB, Dimbil M, Erdman CB, et al. The weber effect and the United States Food And Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37(4):283–294.
   PubMed Web of Science ®Google Scholar
• Chhabra P, Chen X, Weiss SR. Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA Adverse Event Reporting System data. Drug Saf. 2013;36(11):1117–1123.
   PubMed Web of Science ®Google Scholar
• Hartnell NR, Wilson JP. Replication of the weber effect using postmarketing adverse event reports voluntarily submitted to the United States food and drug administration. Pharmacotherapy. 2004;24(6):743–749.
   PubMed Web of Science ®Google Scholar
• Arora A, Jalali RK, Vohora D. Relevance of the weber effect in contemporary pharmacovigilance of oncology drugs. Ther Clin Risk Manag. 2017;13:1195–1203.
   PubMed Web of Science ®Google Scholar
• Fukazawa C, Hinomura Y, Kaneko M, et al. Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA. Pharmacoepidemiol Drug Saf. 2018;27(12):1402–1408.
   PubMed Web of Science ®Google Scholar
• Drug safety communication. Available at http://wayback.archive‐it.org/7993/20171115033743/https://www.fda.gov/Drugs/DrugSafety/ucm250913.htm. cited 2018 Aug 7.
   Google Scholar
• Mercaptopurine (purinethol) labeling approved may 27, 2011 (PDF‐60KB). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009053s032lbl.pdf. cited 2018 Aug 7.
   Google Scholar
• Montgomery M, van Santen MM, Biemond BJ, et al. Hepatosplenic T-Cell lymphoma: a population-based study assessing incidence and association with immune-mediated disease. Gastroenterol Hepatol. 2015;11(3):160–163.
   Google Scholar
• Conjugated estrogens (premarin) labelling approved October 28, 2011 (PDF‐310KB). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/004782s162s164s167lb.pdf. cited 2018 Aug 7
   Google Scholar
• Orphan drug act of 1983. Pub L. No. 97–414, 96 Stat. 2049.
   Google Scholar
• FAQs about rare diseases. (2017, November 30). cited 2020 Jul 21, from https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases
   Google Scholar
• Rare diseases. (2020, June 24). cited 2020 Jul 21, from https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/rare-diseases_en
   Google Scholar
• White KD, Abe R, Ardern-Jones M, et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translation. J Allergy Clin Immunol Pract. 2018;6(1):38–69.
   PubMed Web of Science ®Google Scholar
• Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43–47.
   PubMedGoogle Scholar
• Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol. 1990;126(1):37–42.
   PubMedGoogle Scholar
• Hauben M, Maignen F. Does serious consequential masking exist? An update. Pharmacoepidemiol Drug Saf. 2017;26(6):727–729.
   PubMed Web of Science ®Google Scholar
• Salvo F, Leborgne F, Thiessard F, et al. A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France. Drug Saf. 2013;36(7):565–572.
   PubMed Web of Science ®Google Scholar
• Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10(5):407–410.
   PubMed Web of Science ®Google Scholar
• Ahmad SR. Adverse drug event monitoring at the food and drug administration. J Gen Intern Med. 2003;18(1):57–60.
   PubMed Web of Science ®Google Scholar
• Hartnell NR, Wilson JP. Replication of the weber effect using postmarketing adverse event reports voluntarily submitted to the United States food and drug administration. Pharmacotherapy. 2004;24(6):743–749.
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Lanes S, Sack ST. Reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(5):519–523.
   PubMedGoogle Scholar
• U.S. Food & Drug Administration. Questions and answers on FDA’s adverse event reporting system (FAERS). U.S. Department of Health and Human Services; 2018.
   Google Scholar
• Abdulah R, Suwandiman TF, Handayani N, et al. Incidence, causative drugs, and economic consequences of drug-induced SJS, TEN, and SJS-TEN overlap and potential drug-drug interactions during treatment: a retrospective analysis at an Indonesian referral hospital. Ther Clin Risk Manag. 2017;13:919–925.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Kaniwa N, Ueta M, et al. HLA association with antipyretic analgesics-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular surface complications in Japanese patients. Clin Transl Allergy. 2014;4(Suppl 3):89.
   Google Scholar